Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dal?n J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016 Jul; 36(7):987-95.